Business
Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update
Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Co...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.50em\n}\n.prngen5{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.67em\n}\n.prngen3{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.50em\n}\n.prngen4{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.67em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n May 27, 2021\n \n /CNW/ -\n \n \n Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies today announced the financial results for its fiscal first quarter ended\n \n March 31, 2021\n \n and provided a corporate update.\n \n \n \n \n \n \n \n \n \n \n Fiscal First Quarter Highlights and Recent Developments\n \n \n \n \n Completed a qualifying transaction with Vincero Capital Corporation, closed an oversubscribed financing for gross proceeds of\n \n $4,565,900\n \n , and began trading on the TSX-V under the symbol \"RKV\";\n \n \n \n \n Initiated research and development activities pursuant to our research and collaboration agreement with the\n \n University of British Columbia\n \n , including assembling a dedicated research team and launching in-house lead optimization activities with our drug candidates;\n \n \n \n \n Appointed experienced biotechnology industry veteran,\n \n Julie Cherrington\n \n , PhD, to our ...